The Science and Technology Innovation Board's innovative drugs go overseas and "break the circle," with potential overseas BD transactions exceeding USD 12 billion in the first half of the year
Recently, the 2025 World Lung Cancer Conference was held in Barcelona, Spain. Innovative drug companies on the STAR Market, Beigene, Biokin Pharmaceutical, and Dizal Pharmaceutical, all had important research selected for this year's conference oral presentations. The overseas business development of innovative drug companies on the STAR Market has also reached a new peak. Preliminary statistics show that since 2025, innovative drug companies on the STAR Market have completed 14 licensing transactions for pipeline assets, with a total potential transaction amount exceeding $12 billion
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments